Merus N.V. to Showcase Petosemtamab at Major Cancer Conference
At an upcoming international cancer conference, Merus N.V. is prepared to present groundbreaking findings on petosemtamab, a treatment designed for metastatic colorectal cancer. This significant event will feature both oral and poster presentations, providing valuable insights into the latest advancements in oncology therapeutics.
Event Details and Presentations
The presentations will take place during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled in Boston. The oral presentation, led by Dr. Moh’d Khushman from Washington University, will share initial data on a phase 2 trial assessing the efficacy of petosemtamab in combination with standard chemotherapy and as a monotherapy option for advanced colorectal cancer.
Key Presentation Highlights
The title of the oral presentation is "Petosemtamab (MCLA-158) monotherapy or with chemotherapy in metastatic colorectal cancer: Preliminary antitumor activity and safety data from a phase 2 trial." This will take place on Friday morning, providing attendees with crucial information about the ongoing development of this promising treatment.
Further Investigations on Cancer Stem Cells
Merus will also present a poster focused on the preclinical evaluation of petosemtamab on cancer stem cells. This investigation aims to understand how the treatment interacts with these resilient cell types, potentially offering additional therapeutic strategies for combating colorectal cancer.
Understanding Petosemtamab
Petosemtamab, or MCLA-158, represents a significant innovation in cancer therapy. This fully human antibody targets both the epidermal growth factor receptor (EGFR) and LGR5, a receptor associated with cancer stem cells. Its unique mechanisms of action hold promise for enhancing anti-tumor responses.
Mechanisms of Action
The design of petosemtamab incorporates three main functional activities. It inhibits EGFR-dependent signaling, leads to the degradation of LGR5 through internalization, and boosts antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). These mechanisms may enhance the efficacy of treatments for patients suffering from advanced metastatic colorectal cancer.
About Merus N.V.
As an innovative oncology company, Merus is on the forefront of developing bispecific and trispecific antibody therapies, known as Multiclonics®. These treatments have shown promise in both preclinical and clinical settings, similar to traditional human monoclonal antibodies in terms of their durability and low likelihood of causing immune reactions. Merus is dedicated to advancing cancer treatment and continuously updates its portfolio with novel therapeutic options.
Frequently Asked Questions
What is the main purpose of the presentations at the conference?
The primary aim is to share findings on the efficacy and safety of petosemtamab for treating metastatic colorectal cancer.
Who will present the findings?
Dr. Moh’d Khushman from Washington University School of Medicine will lead the oral presentation.
What makes petosemtamab unique?
Petosemtamab is a bispecific antibody targeting both EGFR and LGR5, designed to provide multiple mechanisms of action against cancer.
When will the abstracts be available?
The abstracts will be available in the conference app, starting on October 22.
How can the public learn more about Merus’ research?
Detailed information and updates can be found on Merus’ official website and social media channels.
